Thymosin alpha 1 is a 28-amino-acid peptide first isolated from calf thymus in 1972 by Allan Goldstein and colleagues at Albert Einstein College of Medicine. Unlike many longevity peptides on the consumer market, it has a substantial clinical development history. It’s approved in over 35 countries (Zadaxin, made by SciClone) for hepatitis B, hepatitis C, and as an adjunct in immunocompromised patients. It’s been studied in dozens of randomized trials over four decades.<\/p>\n
In the US, thymosin alpha 1 has had a complicated regulatory history. It never received FDA approval for any indication. For years it was prepared by compounding pharmacies under section 503A of the Food, Drug, and Cosmetic Act, which allows compounding of bulk drug substances on a case-by-case basis. In 2023, FDA reviewed its inclusion on the 503A bulks list and the peptide was moved into a more restricted status. Some compounding pharmacies stopped offering it; others continued through different regulatory pathways.<\/p>\n
The peptide is genuinely interesting from an immunology standpoint, with real but limited data, and a real but limited place in clinical practice. Marketing around it for general longevity goes well beyond the evidence.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Thymosin alpha 1 is a 28-amino-acid acetylated peptide, sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn.<\/strong> The native protein is generated from a larger precursor called prothymosin alpha through proteolytic processing.<\/p>\n Quick Answer: Thymosin alpha 1 is a 28-amino-acid peptide approved in 35+ countries for hepatitis B and C<\/p>\n Mechanistically, it’s an immunomodulator rather than an immunostimulant. It binds toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells, activating innate immune responses. It also influences T-cell maturation, shifts cytokine profiles toward T-helper 1 responses, and modulates regulatory T-cell function. The combined effect is generally to restore impaired immune responses in immunocompromised hosts without driving inflammatory excess in healthy hosts.<\/p>\n This profile makes it useful in chronic viral infections where the host immune response is exhausted or dysregulated, and potentially in sepsis-related immune paralysis. It’s not a general immune booster in the consumer-supplement sense.<\/p>\n The largest clinical evidence base is in chronic viral hepatitis.<\/strong> Multiple randomized trials in chronic hepatitis B have tested thymosin alpha 1 as monotherapy and in combination with interferon or nucleoside analogs.<\/p>\n A 2003 meta-analysis in Antiviral Therapy by Andreone and colleagues pooled five RCTs in chronic HBV and reported a sustained virologic response rate of 36% with thymosin alpha 1 versus 19% with control at 12 months post-treatment. The effect size was modest but consistent across trials.<\/p>\n For chronic hepatitis C, the data is more variable. Several trials in combination with interferon and ribavirin showed modest additive effects, but the era of direct-acting antivirals like sofosbuvir made interferon-based regimens obsolete. Thymosin alpha 1 isn’t a current standard of care in HCV.<\/p>\n The Zadaxin product is still marketed in Asian and European markets for chronic HBV in patients who can’t tolerate or fail other therapies, though the global market has been reshaped by tenofovir and entecavir.<\/p>\n Thymosin alpha 1 has been studied in melanoma, hepatocellular carcinoma, and several other cancers as an adjunct to standard therapy.<\/strong> A 2009 phase 2 trial in metastatic melanoma combined thymosin alpha 1 with dacarbazine and interferon, with some signal but not enough to drive registration.<\/p>\n In sepsis with immune paralysis, several trials have tested thymosin alpha 1 as adjunct therapy. A 2013 Critical Care RCT in 361 septic patients reported reduced 28-day mortality with thymosin alpha 1 compared with placebo. Other trials haven’t replicated the magnitude of that result, and the indication isn’t standard of care anywhere.<\/p>\n Early in the pandemic, Chinese hospitals reported thymosin alpha 1 use in severe COVID-19 with observational data suggesting reduced mortality.<\/strong> A 2020 observational study in 76 critically ill COVID-19 patients by Liu et al. in Clinical Infectious Diseases reported reduced 28-day mortality in the treated group (11.1% versus 30.0%).<\/p>\n These observational studies had confounding by indication, selection bias, and other limits. Randomized trials of thymosin alpha 1 in COVID-19 produced mixed results. The peptide isn’t part of standard COVID-19 treatment in NIH or WHO guidelines, which focus on dexamethasone, baricitinib, tocilizumab, antiviral remdesivir, and outpatient antivirals like nirmatrelvir\/ritonavir.<\/p>\n Standard Zadaxin dosing is 1.6 mg subcutaneously twice weekly.<\/strong> For chronic HBV the typical course is 26 weeks. For COVID-19 protocols, daily dosing during acute illness was tried with variable durations. For chronic immune support in immunocompromised patients, twice-weekly dosing for 4 to 12 weeks is common.<\/p>\n The half-life is around 2 hours but biological effects persist much longer because the peptide induces durable changes in immune cell populations and signaling. The pharmacokinetics support twice-weekly rather than daily dosing for most chronic indications.<\/p>\n In US compounding-pharmacy-prepared products, dosing was similar, typically 1.6 mg twice weekly subcutaneously, sometimes adjusted to 3.2 mg in patients with more severe immune impairment.<\/p>\n Thymosin alpha 1 has a remarkably clean safety record across decades of use.<\/strong> Reported adverse events in clinical trials are mild and infrequent. Injection site reactions (redness, mild discomfort) are the most common. Some patients report transient headache or fatigue.<\/p>\n No major organ toxicity, no immunogenicity-related serious adverse events, and no signal for autoimmune disease induction has emerged across thousands of patient-years of treatment. This compares favorably to many immune-modulating drugs, which often carry significant toxicity.<\/p>\n In immunocompromised patients receiving thymosin alpha 1, monitoring usually includes complete blood count, liver function, and disease-specific markers (HBV DNA, HCV RNA, tumor markers depending on indication).<\/p>\n In the longevity peptide community, thymosin alpha 1 is positioned as a remedy for age-related thymic involution and the resulting decline in naive T-cell output, vaccine responsiveness, and infection resistance.<\/strong> This is biologically defensible. The thymus does involute with age, T-cell repertoire does narrow, and older adults do have worse outcomes with infection.<\/p>\n Whether thymosin alpha 1 can clinically reverse those changes in otherwise healthy older adults isn’t directly established. Most clinical trial data is in defined disease populations (viral hepatitis, cancer, sepsis), not healthy aging. Anecdotal reports from longevity clinicians suggest subjective improvements in energy, infection resistance, and post-illness recovery, but RCTs in healthy aging haven’t been done.<\/p>\n A reasonable interpretation is that thymosin alpha 1 probably does modulate immune function in older adults consistent with its established pharmacology, and probably is reasonably safe. Whether it produces clinically meaningful long-term benefit is unproven.<\/p>\n Key Takeaway: COVID-19 studies showed mixed results, with some positive observational signal in severe cases<\/p>\n For years, US patients accessed thymosin alpha 1 through compounding pharmacies operating under section 503A.<\/strong> The FDA reviews bulk drug substances eligible for 503A compounding through a public process, and in 2023 thymosin alpha 1 was placed in Category 2 of that review, meaning FDA had identified concerns and the peptide was no longer freely compoundable.<\/p>\n Some compounding pharmacies stopped preparing it. Others continued through clinical study, expanded access, or individual case-by-case prescriptions. The regulatory environment is somewhat unsettled. Patients should expect access through US compounding pharmacies to be variable and to require physician documentation of specific clinical indications.<\/p>\n International availability through Zadaxin remains relatively stable, with some US patients sourcing it abroad through legitimate pharmacies in countries where the drug is approved.<\/p>\n Thymalin is a Russian thymus extract, a polypeptide complex with undefined exact composition.<\/strong> Thymosin alpha 1 is a specific 28-amino-acid synthetic peptide with defined sequence and structure. The two have overlapping mechanisms (both target T-cell function) but very different evidence bases and regulatory status.<\/p>\n Thymosin alpha 1 has the much larger clinical trial database, the international approval for HBV and HCV, and the defined pharmaceutical product. Thymalin is mostly studied in Russian-language literature with limited Western replication.<\/p>\n For US patients, thymosin alpha 1 (when available) is the more defensible choice. Neither is FDA-approved.<\/p>\n Longevity protocols sometimes combine thymosin alpha 1 with thymosin beta 4, BPC-157, or growth hormone secretagogues.<\/strong> The rationale is to address different facets of aging biology, immune function from thymosin alpha 1, tissue repair from thymosin beta 4 and BPC-157, anabolic signaling from GHRH analogs.<\/p>\n These combinations aren’t tested in formal trials. The pharmacological interactions are likely minimal because the peptides target different pathways, but cumulative immune-modulating effects of multiple peptides aren’t characterized. From a precautionary standpoint, single-agent approaches are easier to evaluate for efficacy and side effects.<\/p>\n Thymosin alpha 1 isn’t a weight loss or metabolic peptide.<\/strong> It’s an immune modulator with real but specific clinical roles. For weight loss and cardiometabolic disease, the GLP-1 class is dramatically better-evidenced. STEP 1 (Wilding 2021 NEJM) showed 14.9% weight loss with semaglutide. SURMOUNT-1 (Jastreboff 2022 NEJM) showed 20.9% with tirzepatide at 72 weeks. SELECT (Lincoff 2023 NEJM) showed 20% MACE reduction. FLOW (Perkovic 2024 NEJM) showed 24% kidney and cardiovascular death reduction.<\/p>\n TrimRx offers compounded semaglutide and tirzepatide through a telehealth platform. The free assessment quiz determines if you qualify, and the personalized treatment plan structures therapy around your situation.<\/p>\n For immune support in older adults beyond what thymosin alpha 1 might offer, the evidence-based foundation is annual influenza vaccination, age-appropriate pneumococcal and shingles vaccination, adequate protein intake, resistance training, and vitamin D sufficiency.<\/p>\n Through international Zadaxin distribution, pricing is typically $200 to $500 per month at standard 1.6 mg twice-weekly dosing, depending on country and pharmacy.<\/strong> Through US compounding pharmacies (where available), pricing has run $200 to $400 per month.<\/p>\n These costs aren’t typically covered by US insurance because the product isn’t FDA-approved. Patients pay out-of-pocket. The cost is modest compared with many specialty biologics but meaningful for a peptide that’s typically used for months at a time.<\/p>\n Bottom line: US regulatory status changed in 2023 with restrictions on 503A compounding pharmacy availability<\/p>\n No. It’s approved in over 35 other countries as Zadaxin for hepatitis B and other indications, but the US FDA has never approved it. US compounding pharmacy access was restricted further in 2023.<\/p>\n There’s no published RCT showing thymosin alpha 1 efficacy for long COVID. Some integrative medicine practitioners use it based on immune-modulation rationale, but it isn’t an evidence-based long COVID treatment.<\/p>\n The peptide has been used off-label for general immune support in older adults and people with frequent infections. There’s no RCT in those populations. Anecdotal reports exist but don’t substitute for trial evidence.<\/p>\n Different mechanisms entirely. LDN affects opioid receptor signaling and has anti-inflammatory effects. Thymosin alpha 1 modulates T-cell function and innate immunity through TLR9. They sometimes get used together in chronic illness protocols, but the evidence for either in non-FDA-approved indications is thin.<\/p>\n Different peptides, different functions. Thymosin alpha 1 is an immune modulator. Thymosin beta 4 (TB-500) is involved in actin sequestration, cell migration, and tissue repair. Both come from thymic tissue but have distinct biological roles.<\/p>\n Reported subjective effects on energy or infection resistance often appear within 2 to 4 weeks of starting twice-weekly dosing. Objective immune parameter changes can take 4 to 12 weeks. Sustained therapy of 6 to 12 months is typical in chronic indications.<\/p>\n In clinical trials and decades of use, no clear signal for autoimmune disease induction has emerged. The peptide modulates rather than stimulates immune function, which differs from interferons or strong adjuvants that have shown autoimmune side effect profiles.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Introduction Thymosin alpha 1 is a 28-amino-acid peptide first isolated from calf thymus in 1972 by Allan Goldstein and colleagues at Albert Einstein College…<\/p>\n","protected":false},"author":11,"featured_media":90782,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Thymosin Alpha 1: Immune Modulation & Longevity Applications","_yoast_wpseo_metadesc":"Thymosin alpha 1 is a 28-amino-acid peptide first isolated from calf thymus in 1972 by Allan Goldstein and colleagues at Albert Einstein College of...","_yoast_wpseo_focuskw":"thymosin alpha 1","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[],"class_list":["post-90783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90783"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90783\/revisions"}],"predecessor-version":[{"id":91943,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90783\/revisions\/91943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90782"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Hepatitis B and C Data Show?<\/h2>\n
What About Cancer Adjunct Use?<\/h2>\n
What Did the COVID-19 Studies Show?<\/h2>\n
How Is Thymosin Alpha 1 Dosed in Clinical Use?<\/h2>\n
What Are the Side Effects?<\/h2>\n
What’s the Longevity Peptide Claim?<\/h2>\n
What Changed with US Regulatory Status in 2023?<\/h2>\n
How Does Thymosin Alpha 1 Compare to Thymalin?<\/h2>\n
What About Combination with Other Peptides?<\/h2>\n
How Does This Fit with Metabolic Health?<\/h2>\n
What’s the Cost of Thymosin Alpha 1?<\/h2>\n
FAQ<\/h2>\n
Is Thymosin Alpha 1 FDA-approved?<\/h3>\n
Does Thymosin Alpha 1 Work for Long COVID?<\/h3>\n
Can I Take Thymosin Alpha 1 for General Immune Support?<\/h3>\n
How Does Thymosin Alpha 1 Compare to LDN (Low-dose Naltrexone)?<\/h3>\n
What’s the Difference Between Thymosin Alpha 1 and Thymosin Beta 4?<\/h3>\n
How Long Does It Take to Feel an Effect?<\/h3>\n
Can Thymosin Alpha 1 Trigger Autoimmune Disease?<\/h3>\n